Corrections Of America Stock Earnings Reports

CoreCivic reported strong Q1 2026 operational and financial results driven by higher federal (primarily ICE) and state volumes and the activation of previously idle facilities. Total occupancy for Safety and Community segments rose to 79.6% and average daily population increased to ~57,243. ICE-related revenue surged (ICE revenue +96% YoY), though ICE populations declined ~3,000 from their January peak through April—a decline the company characterizes as temporary. The company activated five idle facilities (including Midwest Regional Reception Center, California City, Diamondback, West Tennessee and Farmville acquisition) and is holding ~7,000 idle beds available for demand. CoreCivic completed the April acquisition of Clinical Solutions Pharmacy (CSP) for $148 million to add a complementary, growing mail-order pharmacy business serving corrections customers; management expects CSP to generate $215M–$230M revenue in 2026 and to contribute ~$0.03–$0.05 to EPS in 2026. Q1 adjusted EBITDA was $110.1M (+36% YoY) and adjusted EPS beat consensus by $0.12. The company repurchased 2.3M shares in Q1 ($44.7M YTD) and has ~$255.8M remaining under authorization; leverage was ~2.8x net debt / adjusted EBITDA. To replenish acquisition funding, CoreCivic added a $100M, 364-day term loan. Updated 2026 guidance was raised: diluted EPS $1.51–$1.61 (adjusted $1.53–$1.63), FFO $2.58–$2.68 (normalized $2.60–$2.70), and adjusted EBITDA $453.8M–$461.8M. Management reiterated prioritization of share repurchases given perceived valuation disconnect, while maintaining capital for accretive M&A and facility activations. Risks include ICE population volatility, government funding/timing, and potential changes in DHS detention strategies (e.g., warehouses or turnkey purchases).